Receive our newsletter – data, insights and analysis delivered to you
September 22, 2011

CardioKinetix secures financing to develop ventricular partitioning device

CardioKinetix has raised $44m in Series E financing to progress the development of the Parachute ventricular partitioning device.

By admin-demo

CardioKinetix has raised $44m in Series E financing to progress the development of the Parachute ventricular partitioning device.

The Parachute device, which recently received the CE Mark, is implanted into the left ventricle of the heart in a simple catheter lab procedure. It is intended to treat patients with heart failure resulting from a heart attack.

CardioKinetix president and CEO Wes Johnson said that the financing allows CardioKinetix to progress the development of the device, which includes conducting clinical studies to further support the initial commercialisation of Parachute in Europe and completing a PMA submission to the US Food and Drug Administration.

The financing was led by SV Life Sciences and New Leaf Venture Partners, US Venture Partners, JP Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management